Letter to the Editor of Radiotherapy and Oncology Regarding of the Article “dosimetric Parameters Related to Occurrence of Distant Metastases and Regional Nodal Relapse after SBRT for Early-Stage Non-Small Cell Lung Cancer” by Lalonde Et Al.

Kaixuan Yang,Chuntang Sun,Rutie Yin
DOI: https://doi.org/10.1016/j.radonc.2022.05.028
IF: 6.901
2022-01-01
Radiotherapy and Oncology
Abstract:The goal of this letter is not to underestimate the work done by Lalonde and colleagues [ [1] Lalonde R. Abdelhakiem M. Keller A. Huq M.S. Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer. Radiother Oncol. 2022; 169: 90-95 Google Scholar ], “Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer” published on Radiotherapy and Oncology in 2022. Instead, this letter intends to draw attention to certain incorrect conclusions concerning four-dimensional CT (4D-CT), which appear to be based on different respiratory motion management strategies in lung cancer radiotherapy [ 1 Lalonde R. Abdelhakiem M. Keller A. Huq M.S. Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer. Radiother Oncol. 2022; 169: 90-95 Google Scholar , 2 Diamant A. Chatterjee A. Faria S. Naqa I.E. Bahig H. Filion E. et al. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?. Radiother Oncol. 2018; 128: 513-519 Google Scholar ]. In this study, the authors conducted a retrospective study involving 304 patients with early-stage NSCLC in US. Their data did not replicate the correlation between lower dose in the periphery of lung SBRT targets and increased rate of distant metastases shown in Diamant et al. published on Radiotherapy and Oncology in 2018 [ [2] Diamant A. Chatterjee A. Faria S. Naqa I.E. Bahig H. Filion E. et al. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?. Radiother Oncol. 2018; 128: 513-519 Google Scholar ]. The results are impressive. However, we have to communicate with the authors regarding several concerns. Response to “Letter to the editor of radiotherapy and oncology regarding of the article “Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer” by Lalonde et al.”Radiotherapy and OncologyVol. 177PreviewWe thank the authors of this letter [1] for their interest in our work [2]. They discuss several concerns about the work, which we will be happy to address. Full-Text PDF
What problem does this paper attempt to address?